Natera, Inc. (NTRA)
| Market Cap | 37.52B +96.4% |
| Revenue (ttm) | 2.50B +36.6% |
| Net Income | -226.32M |
| EPS | -1.64 |
| Shares Out | 143.22M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 699,314 |
| Open | 264.69 |
| Previous Close | 264.69 |
| Day's Range | 260.27 - 266.87 |
| 52-Week Range | 131.81 - 288.04 |
| Beta | 1.50 |
| Analysts | Buy |
| Price Target | 282.14 (+7.69%) |
| Earnings Date | Aug 6, 2026 |
About NTRA
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizo... [Read more]
Financial Performance
In 2025, Natera's revenue was $2.31 billion, an increase of 35.90% compared to the previous year's $1.70 billion. Losses were -$208.16 million, 9.31% more than in 2024.
Financial StatementsAnalyst Summary
According to 22 analysts, the average rating for NTRA stock is "Buy." The 12-month stock price target is $282.14, which is an increase of 7.69% from the latest price.
News
Natera reports results from multicenter study in MCC
Natera (NTRA) announced the publication of results from a prospective, multicenter study in Merkel cell carcinoma, or MCC, published in JAMA Dermatology. The study evaluated the Signatera test against...
Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of results from a prospective, multicenter study i...
Finalized MolDx LCD Includes Expanded Coverage for Natera's Prospera™ Portfolio
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted the impact of a final local coverage determination (LCD) for mol...
Natera price target raised to $325 from $280 at TD Cowen
TD Cowen raised the firm’s price target on Natera (NTRA) to $325 from $280 and keeps a Buy rating on the shares. The firm adjusted targets in the diagnostics group…
Natera price target raised to $330 from $285 at Canaccord
Canaccord raised the firm’s price target on Natera (NTRA) to $330 from $285 and keeps a Buy rating on the shares. The firm updated its model ahead of Q2 results…
Natera price target raised to $310 from $250 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Natera (NTRA) to $310 from $250 and keeps an Overweight rating on the shares. The firm is updating its model ahead of…
Natera announces IVDR certification for Signatera
Natera (NTRA) announced that Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation. The IVDR represents one of the world’s most rigorous…
Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that Signatera has received certification as a Class C device unde...
Natera price target raised to $300 from $270 at Evercore ISI
Evercore ISI raised the firm’s price target on Natera (NTRA) to $300 from $270 and keeps an Outperform rating on the shares. The firm’s Q2 preview for MedTech, Life Sciences…
Natera announces publication evaluating utility of Signatera
Natera (NTRA) announced the publication of new data in JAMA Oncology, evaluating the utility of Signatera, its personalized molecular residual disease test, in patients with resected colorectal liver ...
Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in JAMA Oncology, evaluating the utili...
Natera price target raised to $290 from $270 at Guggenheim
Guggenheim analyst Subbu Nambi raised the firm’s price target on Natera (NTRA) to $290 from $270 and keeps a Buy rating on the shares. The firm adjusted models and forecasts…
Natera, Aveta partner on late-stage head and neck cancer trial
Genetic testing firm Natera and cancer drug developer Aveta Biomics said on Monday they have partnered on a late-stage study of an experimental therapy for head and neck cancer, in a bid to improve ...
Natera, Aveta Biomics announce strategic partnership
Natera (NTRA) and Aveta Biomics announced a strategic partnership supporting AVTA 30-01, Aveta’s global Phase 3 registrational clinical trial evaluating APG-157 in patients with locally advanced head ...
Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer
AUSTIN, Texas & BEDFORD, Mass.--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and Aveta Biomics, Inc., a clinical-stage immuno-oncology company...
Natera resumed with an Outperform at Bernstein
Bernstein analyst Eve Burstein resumed coverage of Natera (NTRA) with an Outperform rating and $310 price target following a return from maternity leave. “Many things” are going right for the…
Natera, Eledon announce strategic partnership
Natera (NTRA) and Eledon Pharmaceuticals (ELDN) announced a strategic partnership to incorporate Natera’s Prospera kidney transplant assessment test into Eledon’s planned Phase 3 clinical trial of teg...
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
AUSTIN, Texas & IRVINE, Calif.--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN), a clinical stage...
Natera price target raised to $275 from $270 at BTIG
BTIG raised the firm’s price target on Natera (NTRA) to $275 from $270 and keeps a Buy rating on the shares following news that Japan’s main regulatory body approved Signatera…
Natera announces Signatera receives regulatory approval in Japan
Natera (NTRA) announced that Signatera has received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency, or PMDA. This approval supports the use of Signatera for patients with ...
Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that Signatera has received regulatory approval from Japan's Pharm...
Natera price target lowered to $260 from $280 at Barclays
Barclays lowered the firm’s price target on Natera (NTRA) to $260 from $280 and keeps an Overweight rating on the shares. The firm adjusted targets in the life science and…
NCCN recommends ctDNA-MRD testing using Signatera technology
Earlier today, the company stated: “Natera (NTRA) announced that the National Comprehensive Cancer Network (NCCN(R)) has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to incl...
Natera price target raised to $270 from $250 at BTIG
BTIG raised the firm’s price target on Natera (NTRA) to $270 from $250 and keeps a Buy rating on the shares. The company’s Signatera has jumped into NCCN guidelines, which…
NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the National Comprehensive Cancer Network® (NCCN®) has update...